Brief: Cleo Diagnostics Says Concluded Design Transfer Activities For Ovarian Cancer Detection Test
12/02/2024 24:44
Feb 12 (Reuters) - Cleo Diagnostics Ltd COV.AX :
* CONCLUDED DESIGN TRANSFER ACTIVITIES RELATING TO CORE
TECHNOLOGY
FOR CO'S OVARIAN CANCER DETECTION TEST
Source text for Eikon: ID:nASX6FCnbc
Further company coverage: COV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CLEO Diagnostics
See all newsBrief: Cleo Diagnostics Raises A$5M
Brief: Cleo Diagnostics Seeks Trading Halt Pending Material Capital Raising Announcement
Brief: Cleo Diagnostics Says Partnership With Entityrisk
Australia's Cleo Diagnostics rises to near 2-month high on US approval for trial
Australia's Cleo Diagnostics jumps on US clinical trials for cancer blood test